

Weekly COVID-19 Breakthrough Infections Report

Clark County, Nevada

Date: February 14, 2023

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.

Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.





Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations

Figure 2:Percentage of Cases among 12 Years and Older By Vaccination Status





	Overall			
٨॥	N %			
All Ago (in yogra)	130322 10	0		
Age (in years) 0-4	10	0		
	1570	0 1		
5-11 12-17		ו 5		
12-17 18-24		0 0		
18-24 25-49	56822 4			
50-64	31059 2			
65+	23768 1			
Gender	23700 1	C		
Male	E600E /			
	56825 4			
Female	72533 5			
Unknown Baco (Ethnicity	964	1		
Race/Ethnicity	20054 2			
Hispanic White	26954 2			
White	41660 3			
Black		8		
API	16718 1	Ŭ		
AEA Other		0		
Other		7		
Unknown Travel Uisterry	25048 1	5		
Travel History	5700			
Yes	0.20	4		
No	36308 2			
Unknown	88294 6	8		
Hospitalization	0.400	_		
Yes		3		
No	41019 3			
Unknown	85900 6	6		
Death	1011			
Yes	1214	1		
No		8		
Unknown	118953 9	1		
Vaccine Type	_	-		
Pfizer	87117 6			
Novavax		0		
Unknown	1123	1		
Moderna	35019 2			
Janssen		5		
Emergen	1	C		
Underlying Conditions				
Yes	20129 1			
No	110193 8	5		

Table 1: Population Characteristics of COVID-19 Breakthrough Cases

Table 2: Breakthrough Case Rates

Fully Vaccinated Population*	Vaccinated Cases	Unvaccinated Population	Unvaccinated Cases	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate per 100K population
880094	130322	1438080	468462	14808	32576



Table 3: Population Characteristics of COVID-19 Breakthrough Hospitalizations

	Overall
	N %
All	3403 100
Age (in years)	
5-11	5 (
12-17	20
18-24	34
25-49	344 10
50-64	591 1
65+	2409 7
Gender	
Male	1850 54
Female	1549 40
Unknown	4 (
Race/Ethnicity	
Hispanic	423 12
White	1986 58
Black	380 1 ⁻
API	335 10
AEA	15 (
Other	103 3
Unknown	161
Travel History	
Yes	144 4
No	1743 5 ⁻
Unknown	1516 4
Death	
Yes	860 2
No	613 18
Unknown	1930 5
Vaccine Type	
Pfizer	1977 58
Unknown	87 3
Moderna	1088 32
Janssen	251
Underlying Conditions	
Yes	2455 72
No	948 28



	Over	Overall	
	Ν	%	
All	1214	100	
Age (in years)			
25-49	37	3	
50-64	146	12	
65+	1031	85	
Gender			
Male	732	60	
Female	482	40	
Race/Ethnicity			
Hispanic	132	11	
White	818	67	
Black	127	10	
API	115	9	
AEA	6	0	
Other	10	1	
Unknown	6	0	
Hospitalization			
Yes	860	71	
No	77	6	
Unknown	277	23	
Vaccine Type			
Pfizer	665	55	
Unknown	29	2	
Moderna	398	33	
Janssen	122	10	
Underlying Conditions			
Yes	695	57	
No	519	43	

Table 4: Population Characteristics of COVID-19 Breakthrough Deaths

Table 5: Breakthrough Death Rates

Fully Vaccinated	Vaccinated	Unvaccinated	Unvaccinated	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate
Population	Deaths	Population	Deaths		per 100K population
880094	1214	1438080	8087	138	562

* Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson & Johnson vaccine.



Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	2455	72
	No	948	28
Hypertension	Yes	1565	N/A
Immunocompromised	Yes	137	N/A
Chronic Heart Disease	Yes	734	N/A
Chronic Liver Disease	Yes	63	N/A
Chronic Kidney Disease	Yes	481	N/A
Diabetes	Yes	915	N/A
Neurologic/Neurodevelopmental	Yes	205	N/A
Chronic Lung Disease	Yes	647	N/A
Historically Healthy	Yes	294	N/A

Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	695	57
	No	519	43
Hypertension	Yes	447	N/A
Immunocompromised	Yes	50	N/A
Chronic Heart Disease	Yes	251	N/A
Chronic Liver Disease	Yes	25	N/A
Chronic Kidney Disease	Yes	189	N/A
Diabetes	Yes	267	N/A
Neurologic/Neurodevelopmental	Yes	61	N/A
Chronic Lung Disease	Yes	198	N/A
Historically Healthy	Yes	26	N/A

Notes:

* White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

* The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

* The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).